High-dose chemotherapy for rhabdomyosarcoma: where do we go from here.
Mackall
C L
CL
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Helman
L J
LJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D002648:Child; D005544:Forecasting; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000401:mortality; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome